Altering the immune response with lipid-based nanoparticles

Journal of Controlled Release

Volumn 161, Issue 2, 2012, Pages 600-608

  Landesman Milo, Dalit ^a   Peer, Dan ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Immune response; Leukocytes; Liposomes; Nanomedicine; RNAi

Indexed keywords

ADVERSE EFFECT; BIODISTRIBUTIONS; CLINICAL PRACTICES; COMMON DENOMINATORS; DELIVERY SYSTEMS; DELIVERY VECTOR; IMMUNE RESPONSE; IMMUNE SYSTEMS; LEUKOCYTES; RNAI; TARGET SITES; THERAPEUTIC BENEFITS;

LIPOSOMES; MEDICAL NANOTECHNOLOGY; NANOPARTICLES;

IMMUNOLOGY;

1,2 DIOLEOYL SN GLYCERO 3 PHOSPHATIDYLCHOLINE; CD40 ANTIGEN; INTERFERON; INTERLEUKIN 10; LIPID BASED NANOPARTICLE; LIPOSOME; MACROGOL; NANOPARTICLE; PHOSPHATIDYLCHOLINE; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

DENDRITIC CELL; DOWN REGULATION; DRUG DELIVERY SYSTEM; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; LEUKOCYTE; MACROPHAGE; MONOCYTE; NONHUMAN; PHAGOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; UPREGULATION;

ANIMALS; HUMANS; IMMUNOMODULATION; LIPIDS; LIPOSOMES; NANOPARTICLES; RNA INTERFERENCE;

EID: 84862691394     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2011.12.034     Document Type: Review

References (110)

1. B.S. Zolnik, A. Gonzalez-Fernandez, N. Sadrieh, M.A. Dobrovolskaia, Nanoparticles and the immune system, Endocrinology 151 (2) (2010) 458-465.
2. P. Nordly, H.B. Madsen, H.M. Nielsen, C. Foged, Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators, Expert Opin. Drug Deliv. 6 (7) (2009) 657-672.
3. M. Cruvinel Wde, D. Mesquita Jr., J.A. Araujo, T.T. Catelan, A.W. de Souza, N.P. da Silva, L.E. Andrade, Immune system - part I. Fundamentals of innate immunity with emphasis on molecular and cellular mechanisms of inflammatory response, Rev. Bras. Reumatol. 50 (4) (2010) 434-461.
4. S.M. Moghimi, D. Peer, R. Langer, Reshaping the future of nanopharmaceuticals: ad iudicium, ACS Nano 5 (11) (2011) 8454-8458.
5. Z. Pancer, M.D. Cooper, The evolution of adaptive immunity, Annu. Rev. Immunol. 24 (2006) 497-518.
6. M.A. Dobrovolskaia, S.E. McNeil, Immunological properties of engineered nanomaterials, Nat. Nanotechnol. 2 (8) (2007) 469-478.
7. A.S. Yazdi, G. Guarda, N. Riteau, S.K. Drexler, A. Tardivel, I. Couillin, J. Tschopp, Nanoparticles activate the NLR pyrin domain containing 3 (Nlrp3) inflammasome and cause pulmonary inflammation through release of IL-1alpha and IL- 1beta, Proc. Natl. Acad. Sci. U. S. A. 107 (45) (2010) 19449-19454.
8. J. Szebeni, S.M. Moghimi, Liposome triggering of innate immune responses: a perspective on benefits and adverse reactions, J. Liposome Res. 19 (2) (2009) 85-90.
9. M. Goldsmith, S. Mizrahy, D. Peer, Grand challenges in modulating the immune response with RNAi nanomedicines, Nanomedicine (Lond.) 6 (10) (2011) 1771-1785.
10. M.L. De Temmerman, J. Rejman, J. Demeester, D.J. Irvine, B. Gander, S.C. De Smedt, Particulate vaccines: on the quest for optimal delivery and immune response, Drug Discov. Today 16 (13-14) (2011) 569-582.
11. R. Kedmi, N. Ben-Arie, D. Peer, The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation, Biomaterials 31 (26) (2010) 6867-6875.
12. D. Peer, E.J. Park, Y. Morishita, C.V. Carman, M. Shimaoka, Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target, Science 319 (5863) (2008) 627-630.
13. T. Maekawa, T.A. Kufer, P. Schulze-Lefert, NLR functions in plant and animal immune systems: so far and yet so close, Nat. Immunol. 12 (9) (2011) 817-826.
14. D. Nemazee, A. Gavin, K. Hoebe, B. Beutler, Immunology: Toll-like receptors and antibody responses, Nature 441 (7091) (2006) E4 discussion E4.
15. K. Hoebe, Z. Jiang, P. Georgel, K. Tabeta, E. Janssen, X. Du, B. Beutler, TLR signaling pathways: opportunities for activation and blockade in pursuit of therapy, Curr. Pharm. Des. 12 (32) (2006) 4123-4134.
16. K. Hoebe, Z. Jiang, K. Tabeta, X. Du, P. Georgel, K. Crozat, B. Beutler, Genetic analysis of innate immunity, Adv. Immunol. 91 (2006) 175-226.
17. T. Maekawa, W. Cheng, L.N. Spiridon, A. Toller, E. Lukasik, Y. Saijo, P. Liu, Q.H. Shen, M.A. Micluta, I.E. Somssich, F.L. Takken, A.J. Petrescu, J. Chai, P. Schulze-Lefert, Coiled-coil domain-dependent homodimerization of intracellular barley immune receptors defines a minimal functional module for triggering cell death, Cell Host Microbe 9 (3) (2011) 187-199.
18. L. Peiser, S. Mukhopadhyay, S. Gordon, Scavenger receptors in innate immunity, Curr. Opin. Immunol. 14 (1) (2002) 123-128.
19. Y. Chao, P.P. Karmali, D. Simberg, Role of carbohydrate receptors in the macrophage uptake of dextran-coated iron oxide nanoparticles, Adv. Exp. Med. Biol. 733 (2012) 115-123.
20. M. Pepper, M.K. Jenkins, Origins of CD4(+) effector and central memory T cells, Nat. Immunol. 12 (6) (2011) 467-471.
21. T.H. Nguyen, T.B. Casale, Immune modulation for treatment of allergic disease, Immunol. Rev. 242 (1) (2011) 258-271.
22. D.R. Littman, A.Y. Rudensky, Th17 and regulatory T cells in mediating and restraining inflammation, Cell 140 (6) (2010) 845-858.
23. S. Eyerich, K. Eyerich, D. Pennino, T. Carbone, F. Nasorri, S. Pallotta, F. Cianfarani, T. Odorisio, C. Traidl-Hoffmann, H. Behrendt, S.R. Durham, C.B. Schmidt-Weber, A. Cavani, Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling, J. Clin. Invest. 119 (12) (2009) 3573-3585.
24. L. Zhou, M.M. Chong, D.R. Littman, Plasticity of CD4+ T cell lineage differentiation, Immunity 30 (5) (2009) 646-655.
25. A.M. Leen, C.M. Rooney, A.E. Foster, Improving T cell therapy for cancer, Annu. Rev. Immunol. 25 (2007) 243-265.
26. M.T. Liang, N.M. Davies, J.T. Blanchfield, I. Toth, Particulate systems as adjuvants and carriers for peptide and protein antigens, Curr. Drug Deliv. 3 (4) (2006) 379-388.
27. D. Peer, M. Shimaoka, Systemic siRNA delivery to leukocyte-implicated diseases, Cell Cycle 8 (6) (2009) 853-859.
28. T. Fifis, A. Gamvrellis, B. Crimeen-Irwin, G.A. Pietersz, J. Li, P.L. Mottram, I.F. McKenzie, M. Plebanski, Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors, J. Immunol. 173 (5) (2004) 3148-3154.
29. P.L. Mottram, D. Leong, B. Crimeen-Irwin, S. Gloster, S.D. Xiang, J. Meanger, R. Ghildyal, N. Vardaxis, M. Plebanski, Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus, Mol. Pharm. 4 (1) (2007) 73-84.
30. N. Scholer, H. Hahn, R.H. Muller, O. Liesenfeld, Effect of lipid matrix and size of solid lipid nanoparticles (SLN) on the viability and cytokine production of macrophages, Int. J. Pharm. 231 (2) (2002) 167-176.
31. Y. Chen, S.R. Bathula, J. Li, L. Huang, Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer, J. Biol. Chem. 285 (29) (2010) 22639-22650.
32. D. Christensen, K.S. Korsholm, I. Rosenkrands, T. Lindenstrom, P. Andersen, E.M. Agger, Cationic liposomes as vaccine adjuvants, Expert Rev. Vaccines 6 (5) (2007) 785-796.
33. T. Nakanishi, J. Kunisawa, A. Hayashi, Y. Tsutsumi, K. Kubo, S. Nakagawa, H. Fujiwara, T. Hamaoka, T. Mayumi, Positively charged liposome functions as an efficient immunoadjuvant in inducing immune responses to soluble proteins, Biochem. Biophys. Res. Commun. 240 (3) (1997) 793-797.
34. S. Spagnou, A.D. Miller, M. Keller, Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA, Biochemistry 43 (42) (2004) 13348-13356.
35. D.P. Vangasseri, Z. Cui, W. Chen, D.A. Hokey, L.D. Falo Jr., L. Huang, Immunostimulation of dendritic cells by cationic liposomes, Mol. Membr. Biol. 23 (5) (2006) 385-395.
36. L.J. Solmesky, M. Shuman, M. Goldsmith, M. Weil, D. Peer, Assessing cellular toxicities in fibroblasts upon exposure to lipid-based nanoparticles: a high content analysis approach, Nanotechnology 22 (49) (2011) 494016.
37. A. Chanan-Khan, J. Szebeni, S. Savay, L. Liebes, N.M. Rafique, C.R. Alving, F.M. Muggia, Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions, Ann. Oncol. 14 (9) (2003) 1430-1437.
38. J. Szebeni, P. Bedocs, Z. Rozsnyay, Z. Weiszhar, R. Urbanics, L. Rosivall, R. Cohen, O. Garbuzenko, G. Bathori, M. Toth, R. Bunger, Y. Barenholz, Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome, Nanomedicine (2011) (Electronic publication ahead of print).
39. J. Szebeni, F. Muggia, A. Gabizon, Y. Barenholz, Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention, Adv. Drug Deliv. Rev. 63 (12) (2011) 1020-1030.
40. D. Mohanan, B. Slutter, M. Henriksen-Lacey, W. Jiskoot, J.A. Bouwstra, Y. Perrie, T.M. Kundig, B. Gander, P. Johansen, Administration routes affect the quality of immune responses: a cross-sectional evaluation of particulate antigen-delivery systems, J. Control. Release 147 (3) (2010) 342-349.
41. R. Ravindran, M. Maji, N. Ali, Vaccination with Liposomal Leishmanial Antigens adjuvanted with MPL-TDM Confers Long-term Protection against Visceral Leishmaniasis through Human Adminstrable Route, Mol. Pharmaceutics 9 (1) (2011) 59-70.
42. D. Gutman, H. Epstein-Barash, M. Tsuriel, G. Golomb, Alendronate liposomes for antitumor therapy: activation of gammadelta T cells and inhibition of tumor growth, Adv. Exp. Med. Biol. 733 (2012) 165-179.
43. Y. Ikehara, M. Yamanaka, T. Yamaguchi, Recent advancements in cytotoxic T lymphocyte generation methods using carbohydrate-coated liposomes, J. Biomed. Biotechnol. 2010 (2010) 242539.
44. N. Scholer, C. Olbrich, K. Tabatt, R.H. Muller, H. Hahn, O. Liesenfeld, Surfactant, but not the size of solid lipid nanoparticles (SLN) influences viability and cytokine production of macrophages, Int. J. Pharm. 221 (1-2) (2001) 57-67.
45. H. Vallhov, J. Qin, S.M. Johansson, N. Ahlborg, M.A. Muhammed, A. Scheynius, S. Gabrielsson, The importance of an endotoxin-free environment during the production of nanoparticles used in medical applications, Nano Lett. 6 (8) (2006) 1682-1686.
46. B. Ozpolat, A.K. Sood, G. Lopez-Berestein, Nanomedicine based approaches for the delivery of siRNA in cancer, J. Intern. Med. 267 (1) (2010) 44-53.
47. K. Buyens, S.C. De Smedt, K. Braeckmans, J. Demeester, L. Peeters, L.A. van Grunsven, X. de Mollerat du Jeu, R. Sawant, V. Torchilin, K. Farkasova, M. Ogris, N.N. Sanders, Liposome based systems for systemic siRNA delivery: Stability in blood sets the requirements for optimal carrier design, J. Control. Release (2011).
48. R.S. Shirazi, K.K. Ewert, C. Leal, R.N. Majzoub, N.F. Bouxsein, C.R. Safinya, Synthesis and characterization of degradable multivalent cationic lipids with disulfidebond spacers for gene delivery, Biochim. Biophys. Acta 1808 (9) (2011) 2156-2166.
49. A. Akinc, A. Zumbuehl, M. Goldberg, E.S. Leshchiner, V. Busini, N. Hossain, S.A. Bacallado, D.N. Nguyen, J. Fuller, R. Alvarez, A. Borodovsky, T. Borland, R. Constien, A. de Fougerolles, J.R. Dorkin, K. Narayanannair Jayaprakash, M. Jayaraman, M. John, V. Koteliansky, M. Manoharan, L. Nechev, J. Qin, T. Racie, D. Raitcheva, K.G. Rajeev, D.W. Sah, J. Soutschek, I. Toudjarska, H.P. Vornlocher, T.S. Zimmermann, R. Langer, D.G. Anderson, A combinatorial library of lipid-likematerials for delivery of RNAi therapeutics, Nat. Biotechnol. 26 (5) (2008) 561-569.
50. C. Lonez, M. Vandenbranden, J.M. Ruysschaert, Cationic liposomal lipids: from gene carriers to cell signaling, Prog. Lipid Res. 47 (5) (2008) 340-347.
51. T. Harel-Adar, T. Ben Mordechai, Y. Amsalem, M.S. Feinberg, J. Leor, S. Cohen, Modulation of cardiac macrophages by phosphatidylserine-presenting liposomes improves infarct repair, Proc. Natl. Acad. Sci. U. S. A. 108 (5) (2011) 1827-1832.
52. T.M. Allen, C. Hansen, F. Martin, C. Redemann, A. Yau-Young, Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo, Biochim. Biophys. Acta 1066 (1) (1991) 29-36.
53. A.L. Klibanov, K. Maruyama, V.P. Torchilin, L. Huang, Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes, FEBS Lett. 268 (1) (1990) 235-237.
54. T. Ishida, R. Maeda, M. Ichihara, K. Irimura, H. Kiwada, Accelerated clearance of PEGylated liposomes in rats after repeated injections, J. Control. Release 88 (1) (2003) 35-42.
55. T. Ishida, K. Masuda, T. Ichikawa, M. Ichihara, K. Irimura, H. Kiwada, Accelerated clearance of a second injection of PEGylated liposomes in mice, Int. J. Pharm. 255 (1-2) (2003) 167-174.
56. T. Ishida, X. Wang, T. Shimizu, K. Nawata, H. Kiwada, PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner, J. Control. Release 122 (3) (2007) 349-355.
57. C.R. Miller, B. Bondurant, S.D. McLean, K.A. McGovern, D.F. O'Brien, Liposome-cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes, Biochemistry 37 (37) (1998) 12875-12883.
58. C. Foged, C. Arigita, A. Sundblad, W. Jiskoot, G. Storm, S. Frokjaer, Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition, Vaccine 22 (15-16) (2004) 1903-1913.
59. M.J. Gray, G. Van Buren, N.A. Dallas, L. Xia, X.Wang, A.D. Yang, R.J. Somcio, Y.G. Lin, S. Lim, F. Fan, L.S. Mangala, T. Arumugam, C.D. Logsdon, G. Lopez-Berestein, A.K. Sood, L.M. Ellis, Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver, J. Natl. Cancer Inst. 100 (2) (2008) 109-120.
60. J. Halder, A.A. Kamat, C.N. Landen Jr., L.Y. Han, S.K. Lutgendorf, Y.G. Lin, W.M. Merritt, N.B. Jennings, A. Chavez-Reyes, R.L. Coleman, D.M. Gershenson, R. Schmandt, S.W. Cole, G. Lopez-Berestein, A.K. Sood, Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy, Clin. Cancer Res. 12 (16) (2006) 4916-4924.
61. C.N. Landen Jr., A. Chavez-Reyes, C. Bucana, R. Schmandt, M.T. Deavers, G. Lopez-Berestein, A.K. Sood, Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery, Cancer Res. 65 (15) (2005) 6910-6918.
62. W.M. Merritt, Y.G. Lin, W.A. Spannuth, M.S. Fletcher, A.A. Kamat, L.Y. Han, C.N. Landen, N. Jennings, K. De Geest, R.R. Langley, G. Villares, A. Sanguino, S.K. Lutgendorf, G. Lopez-Berestein, M.M. Bar-Eli, A.K. Sood, Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth, J. Natl. Cancer Inst. 100 (5) (2008) 359-372.
63. A.M. Gewirtz, On future's doorstep: RNA interference and the pharmacopeia of tomorrow, J. Clin. Invest. 117 (12) (2007) 3612-3614.
64. T. Tanaka, L.S. Mangala, P.E. Vivas-Mejia, R. Nieves-Alicea, A.P. Mann, E. Mora, H.D. Han, M.M. Shahzad, X. Liu, R. Bhavane, J. Gu, J.R. Fakhoury, C. Chiappini, C. Lu, K. Matsuo, B. Godin, R.L. Stone, A.M. Nick, G. Lopez-Berestein, A.K. Sood, M. Ferrari, Sustained small interfering RNA delivery by mesoporous silicon particles, Cancer Res. 70 (9) (2010) 3687-3696.
65. D. Peer, J. Lieberman, Special delivery: targeted therapy with small RNAs, Gene Ther. 18 (12) (2011) 1127-1133.
66. G.J. Villares, M. Zigler, H. Wang, V.O. Melnikova, H. Wu, R. Friedman, M.C. Leslie, P.E. Vivas-Mejia, G. Lopez-Berestein, A.K. Sood, M. Bar-Eli, Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA, Cancer Res. 68 (21) (2008) 9078-9086.
67. S6: preclinical safety evaluation of biotechnology-derived pharmaceuticalsin, Fed. Regist. 62 (1997) 61515.
68. International Conference on Harmonisation; Guidance on S8 Immunotoxicity Studies for Human Pharmaceuticals; availability. Notice, Fed. Regist. 71 (71) (2006) 19193-19194.
69. J. Szebeni, C.R. Alving, L. Rosivall, R. Bunger, L. Baranyi, P. Bedocs, M. Toth, Y. Barenholz, Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles, J. Liposome Res. 17 (2) (2007) 107-117.
70. E. Haber, E. Afergan, H. Epstein, D. Gutman, N. Koroukhov, M. Ben-David, M. Schachter, G. Golomb, Route of administration-dependent anti-inflammatory effect of liposomal alendronate, J. Control. Release 148 (2) (2010) 226-233.
71. J. Szebeni, L. Baranyi, S. Savay, J. Milosevits, R. Bunger, P. Laverman, J.M.Metselaar, G. Storm, A. Chanan-Khan, L. Liebes, F.M. Muggia, R. Cohen, Y. Barenholz, C.R. Alving, Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: experimental and clinical studies, J. Liposome Res. 12 (1-2) (2002) 165-172.
72. H. Epstein, D. Gutman, E. Cohen-Sela, E. Haber, O. Elmalak, N. Koroukhov, H.D. Danenberg, G. Golomb, Preparation of alendronate liposomes for enhanced stability and bioactivity: in vitro and in vivo characterization, AAPS J. 10 (4) (2008) 505-515.
73. P.J. Richards, B.D. Williams, A.S. Williams, Suppression of chronic streptococcal cell wall-induced arthritis in Lewis rats by liposomal clodronate, Rheumatology (Oxford) 40 (9) (2001) 978-987.
74. T.P. Slegers, N. van Rooijen, G. van Rij, R. van der Gaag, Delayed graft rejection in pre-vascularised corneas after subconjunctival injection of clodronate liposomes, Curr. Eye Res. 20 (4) (2000) 322-324.
75. S.M. Zeisberger, B. Odermatt, C. Marty, A.H. Zehnder-Fjallman, K. Ballmer-Hofer, R.A. Schwendener, Clodronate-liposome-mediated depletion of tumourassociated macrophages: a new and highly effective antiangiogenic therapy approach, Br. J. Cancer 95 (3) (2006) 272-281.
76. N.G. Frangogiannis, C.W. Smith, M.L. Entman, The inflammatory response in myocardial infarction, Cardiovasc. Res. 53 (1) (2002) 31-47.
77. J.E. Mitchell, M. Cvetanovic, N. Tibrewal, V. Patel, O.R. Colamonici, M.O. Li, R.A. Flavell, J.S. Levine, R.B. Birge, D.S. Ucker, The presumptive phosphatidylserine receptor is dispensable for innate anti-inflammatory recognition and clearance of apoptotic cells, J. Biol. Chem. 281 (9) (2006) 5718-5725.
78. S.A. Rosenberg, Progress in the development of immunotherapy for the treatment of patients with cancer, J. Intern. Med. 250 (6) (2001) 462-475.
79. S.A. Rosenberg, J.C. Yang, N.P. Restifo, Cancer immunotherapy: moving beyond current vaccines, Nat. Med. 10 (9) (2004) 909-915.
80. Y. Ikehara, N. Shiuchi, S. Kabata-Ikehara, H. Nakanishi, N. Yokoyama, H. Takagi, T. Nagata, Y. Koide, K. Kuzushima, T. Takahashi, K. Tsujimura, N. Kojima, Effective induction of anti-tumor immune responses with oligomannose-coated liposome targeting to intraperitoneal phagocytic cells, Cancer Lett. 260 (1-2) (2008) 137-145.
81. N. Kojima, L. Biao, T. Nakayama, M. Ishii, Y. Ikehara, K. Tsujimura, Oligomannose-coated liposomes as a therapeutic antigen-delivery and an adjuvant vehicle for induction of in vivo tumor immunity, J. Control. Release 129 (1) (2008) 26-32.
82. Y. Nishikawa, H. Zhang, Y. Ikehara, N. Kojima, X. Xuan, N. Yokoyama, Immunization with oligomannose-coated liposome-entrapped dense granule protein 7 protects dams and offspring from Neospora caninum infection in mice, Clin. Vaccine Immunol. 16 (6) (2009) 792-797.
83. Y. Ikehara, T. Niwa, L. Biao, S.K. Ikehara, N. Ohashi, T. Kobayashi, Y. Shimizu, N. Kojima, H. Nakanishi, A carbohydrate recognition-based drug delivery and controlled release system using intraperitoneal macrophages as a cellular vehicle, Cancer Res. 66 (17) (2006) 8740-8748.
84. Y. Ikehara, M. Yamanaka, T. Yamaguchi, Recent advancements in cytotoxic T lymphocyte generation methods using carbohydrate-coated liposomes, J. Biomed. Biotechnol. (2010) 242539.
85. M. Amin, M.R. Jaafari, M. Tafaghodi, Impact of chitosan coating of anionic liposomes on clearance rate, mucosal and systemic immune responses following nasal administration in rabbits, Colloids Surf. B Biointerfaces 74 (1) (2009) 225-229.
86. A. Fire, S. Xu, M.K. Montgomery, S.A. Kostas, S.E. Driver, C.C. Mello, Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans, Nature 391 (6669) (1998) 806-811.
87. D. Peer, J. Lieberman, Special delivery: targeted therapy with small RNAs, Gene Ther. 18 (12) (2011) 1127-1133.
88. S. Akhtar, I.F. Benter, Nonviral delivery of synthetic siRNAs in vivo, J. Clin. Invest. 117 (12) (2007) 3623-3632.
89. D.H. Kim, J.J. Rossi, Strategies for silencing human disease using RNA interference, Nat. Rev. Genet. 8 (3) (2007) 173-184.
90. D. Grimm, K.L. Streetz, C.L. Jopling, T.A. Storm, K. Pandey, C.R. Davis, P. Marion, F. Salazar, M.A. Kay, Fatality in mice due to oversaturation of cellular microRNA/-short hairpin RNA pathways, Nature 441 (7092) (2006) 537-541.
91. M.E. Kleinman, K. Yamada, A. Takeda, V. Chandrasekaran, M. Nozaki, J.Z. Baffi, R.J. Albuquerque, S. Yamasaki, M. Itaya, Y. Pan, B. Appukuttan, D. Gibbs, Z. Yang, K. Kariko, B.K. Ambati, T.A. Wilgus, L.A. DiPietro, E. Sakurai, K. Zhang, J.R. Smith, E.W. Taylor, J. Ambati, Sequence- and target-independent angiogenesis suppression by siRNA via TLR3, Nature 452 (7187) (2008) 591-597.
92. M.A. Behlke, Chemical modification of siRNAs for in vivo use, Oligonucleotides 18 (4) (2008) 305-319.
93. K.A. Lennox, M.A. Behlke, Chemical modification and design of anti-miRNA oligonucleotides, Gene Ther. 18 (12) (2011) 1111-1120.
94. A.K. Iyer, G. Khaled, J. Fang,H.Maeda, Exploiting the enhanced permeability and retention effect for tumor targeting, Drug Discov. Today 11 (17-18) (2006) 812-818.
95. D. Peer, J.M. Karp, S. Hong, O.C. Farokhzad, R. Margalit, R. Langer, Nanocarriers as an emerging platform for cancer therapy, Nat. Nanotechnol. 2 (12) (2007) 751-760.
96. P. Couvreur, C. Vauthier, Nanotechnology: intelligent design to treat complex disease, Pharm. Res. 23 (7) (2006) 1417-1450.
97. F. Yuan, M. Dellian, D. Fukumura, M. Leunig, D.A. Berk, V.P. Torchilin, R.K. Jain, Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size, Cancer Res. 55 (17) (1995) 3752-3756.
98. V.P. Torchilin, Recent advances with liposomes as pharmaceutical carriers, Nat. Rev. Drug Discov. 4 (2) (2005) 145-160.
99. H. Maeda, T. Sawa, T. Konno, Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS, J. Control. Release 74 (1-3) (2001) 47-61.
100. Y. Matsumura, H. Maeda, A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS, Cancer Res. 46 (12 Pt 1) (1986) 6387-6392.
101. N. Manjunath, D.M. Dykxhoorn, Advances in synthetic siRNA delivery, Discov. Med. 9 (48) (2010) 418-430.
102. M. Dominska, D.M. Dykxhoorn, Breaking down the barriers: siRNA delivery and endosome escape, J. Cell Sci. 123 (Pt 8) (2010) 1183-1189.
103. K. Tiemann, J.J. Rossi, RNAi-based therapeutics-current status, challenges and prospects, EMBO Mol. Med. 1 (3) (2009) 142-151.
104. Z. Huang, M.R. King, An immobilized nanoparticle-based platform for efficient gene knockdown of targeted cells in the circulation, Gene Ther. 16 (10) (2009) 1271-1282.
105. D. Peer, P. Zhu, C.V. Carman, J. Lieberman, M. Shimaoka, Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte functionassociated antigen-1, Proc. Natl. Acad. Sci. U. S. A. 104 (10) (2007) 4095-4100.
106. R. Elfakess, D. Peer, Overcoming RNAi transduction in leukocytes using targeted and stabilized nanoparticles, IDrugs 13 (9) (2010) 626-631.
107. X. Zheng, C. Vladau, X. Zhang, M. Suzuki, T.E. Ichim, Z.X. Zhang, M. Li, E. Carrier, B. Garcia, A.M. Jevnikar, W.P. Min, A novel in vivo siRNA delivery system specifically targeting dendritic cells and silencing CD40 genes for immunomodulation, Blood 113 (12) (2009) 2646-2654.
108. S.S. Kim, D. Peer, P. Kumar, S. Subramanya, H. Wu, D. Asthana, K. Habiro, Y.G. Yang, N. Manjunath, M. Shimaoka, P. Shankar, RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice, Mol. Ther. 18 (2) (2010) 370-376.
109. S.S. Kim, S. Subramanya, D. Peer, M. Shimaoka, P. Shankar, Antibody-mediated delivery of siRNAs for anti-HIV therapy, Methods Mol. Biol. 721 (2011) 339-353.
110. N. Ben-Arie, R. Kedmi, D. Peer, Integrin-targeted nanoparticles for siRNA delivery, Methods Mol. Biol. 757 (2012) 497-507.